Vepdegestrant extends progression-free survival in ER-positive, HER2-negative breast cancer
1. In this randomized controlled trial, vepdegestrant achieved a longer progression-free survival than fulvestrant in patients with advanced ER-positive, HER2-negative breast cancer. 2. Vepdegestrant demonstrated an acceptable safety profile and was associated with a low rate of discontinuation due to adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Cyclin-dependent kinase 4 and 6 (CDK4/6) […]
The post Vepdegestrant extends progression-free survival in ER-positive, HER2-negative breast cancer first appeared on 2 Minute Medicine.Source: 2 Minute Medicine